MDICT Task Force

The Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT) is an international task force of leading phase 1 and 2 investigators, supported by the NDDO Education Foundation. Its mission is to develop practical guidance on the optimal development of innovative anticancer agents, in particular targeted agents.

The next MDICT Task Force meeting has been scheduled for March 7, 2012. The topic of discussion will be "Early-phase development of combinations of targeted anticancer agents". A verbal report of this meeting will be presented in one of the TAT 2012 sessions. Check the updated TAT 2012 schedule for details.

Annual meetings
The Task Force meets annually in conjunction with the TAT meeting. Participation in meetings is by personal invitation only. Observers with a relevant role in oncology drug development in industry, governmental or regulatory agencies are welcome to attend. If you are interested in joining the Task Force at its next meeting, either as an active clinical investigator or an observer, contact the TAT Secretariat ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ). The next meeting will be scheduled just before the opening of TAT 2012012.

MDICT reports
Reports of MDICT meetings held in 2006 - 2010 have been published in the European Journal of Cancer (1-4). A paper on the outcomes of the 2010 meeting is under preparation. A review of the first years of MDICT is in press (5).

1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:19-24. Abstract.

2. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:25-29. Abstract.

3. Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2009;45:741-746. Abstract.

4. Goodwin R, Giaccone G, Calvert H, Lobezoo M, Eisenhauer EA. Targeted agents: How to select the winners in preclinical and early clinical studies? Eur J Cancer 2011. Abstract.

5. Lobbezoo MW, Calvert AH, Eisenhauer EA, Giaccone G. MDICT Task Force addresses methodological issues in the clinical development of innovative cancer therapies. Clinical Invest (in press).